Krystal Biotech (KRYS) Gets a Buy Rating from Chardan Capital

By Jason Carr

In a report released today, Gbola Amusa from Chardan Capital reiterated a Buy rating on Krystal Biotech (KRYSResearch Report), with a price target of $100.00. The company’s shares closed last Monday at $49.82.

According to, Amusa is a top 100 analyst with an average return of 24.0% and a 48.9% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Adverum Biotechnologies, and Catalyst Biosciences.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Krystal Biotech with a $90.00 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $66.85 and a one-year low of $18.50. Currently, Krystal Biotech has an average volume of 150.9K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Krystal Biotech, Inc. is a gene therapy company, which engages in developing and commercializing treatment for patients suffering from dermatological diseases. It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases for which company believe there are no known effective treatments. The company was founded by Suma M. Krishnan in December 2017 and is headquartered in Pittsburgh, PA.